• AstraZeneca divests Atacand commercial rights to Cheplapharm pharmaceutical-technology.
    January 06, 2021
    AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to German pharmaceutical firm Cheplapharm Arzneimittel.
  • AstraZeneca to Sell Atacand, Atacand Plus Commercial Rights to Cheplapharm americanpharmaceuticalreview
    November 06, 2020
  • Atacand to be divested to Cheplapharm in Europe worldpharmanews
    July 25, 2018
PharmaSources Customer Service